Identification

Name
Thioproperazine
Accession Number
DB01622
Type
Small Molecule
Groups
Approved
Description

Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually without antiserotonin and hypotensive action and has no antihistaminic property. It is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. Overdosage may result in severe extrapyramidal symptoms with dysphagia, marked sialorrhea, persistent and rapidly increasing hyperthermia, pulmonary syndrome, state of shock with pallor and profuse sweating, which may be followed by collapse and coma. LD50 in mice is 70 mg/kg I.V., 120 mg/kg I.P., 500 mg/kg S.C. and 830 mg/kg P.O.

Structure
Thumb
Synonyms
  • (Thioproperazine)-2-dimethylsulfamido-(10-(3-1-methylpiperazinyl-4)propyl)-phenothiazine
  • 2-Dimethylsulfamido-(10-(3-1-methylpiperazinyl-4)propyl)-phenothiazine
  • N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine-2-sulfonamide
  • N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine-2-sulfonamide
  • Thioperazine
  • Thioproperazin
  • Thioproperazinum
  • Tioproferazina
  • Tioproperazina
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Majeptil Tab 10mgTablet10 mgOralErfa Canada 2012 Inc1962-12-31Not applicableCanada
International/Other Brands
Majeptil
Categories
UNII
YJ050AQ56X
CAS number
316-81-4
Weight
Average: 446.629
Monoisotopic: 446.181017604
Chemical Formula
C22H30N4O2S2
InChI Key
VZYCZNZBPPHOFY-UHFFFAOYSA-N
InChI
InChI=1S/C22H30N4O2S2/c1-23(2)30(27,28)18-9-10-22-20(17-18)26(19-7-4-5-8-21(19)29-22)12-6-11-25-15-13-24(3)14-16-25/h4-5,7-10,17H,6,11-16H2,1-3H3
IUPAC Name
N,N-dimethyl-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine-2-sulfonamide
SMILES
CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1

Pharmacology

Indication

For the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.

Associated Conditions
Pharmacodynamics

Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually without antiserotonin and hypotensive action and has no antihistaminic property.

Mechanism of action

Thioproperazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 1A
antagonist
Human
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Overdosage may result in severe extrapyramidal symptoms with dysphagia, marked sialorrhea, persistent and rapidly increasing hyperthermia, pulmonary syndrome, state of shock with pallor and profuse sweating, which may be followed by collapse and coma. LD50 in mice is 70 mg/kg I.V., 120 mg/kg I.P., 500 mg/kg S.C. and 830 mg/kg P.O.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThioproperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThioproperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThioproperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThioproperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThioproperazine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Thioproperazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved, Investigational
AcepromazineAcepromazine may increase the antihypertensive activities of Thioproperazine.Approved, Vet Approved
AdrafinilThioproperazine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Thioproperazine.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Alaproclate.Experimental
AlfentanilThioproperazine may increase the hypotensive activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Thioproperazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlphacetylmethadolThioproperazine may increase the hypotensive activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineThioproperazine may increase the hypotensive activities of Alphaprodine.Illicit
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmantadineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Amantadine.Approved
AmibegronThioproperazine may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe risk or severity of hypotension can be increased when Thioproperazine is combined with Amiodarone.Approved, Investigational
AmisulprideThioproperazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazThioproperazine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Thioproperazine.Approved
AmlodipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Thioproperazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the antihypertensive activities of Thioproperazine.Approved
AmphetamineThioproperazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Thioproperazine is combined with Amrinone.Approved
AnisodamineThioproperazine may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Apomorphine.Approved, Investigational
ApraclonidineThioproperazine may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Aranidipine.Approved, Investigational
ArbutamineThioproperazine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolThioproperazine may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Thioproperazine.Investigational
ArtemetherThe serum concentration of Thioproperazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Thioproperazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Thioproperazine can be increased when it is combined with Artemotil.Approved
ArtenimolThe serum concentration of Thioproperazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Thioproperazine can be increased when it is combined with Artesunate.Approved, Investigational
AsenapineAsenapine may increase the antihypertensive activities of Thioproperazine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
AtovaquoneThe serum concentration of Thioproperazine can be increased when it is combined with Atovaquone.Approved
AvanafilAvanafil may increase the hypotensive activities of Thioproperazine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Thioproperazine is combined with Azimilide.Investigational
BambuterolThioproperazine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarnidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Thioproperazine.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Thioproperazine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Benidipine.Approved, Investigational
BenzphetamineThioproperazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
BepridilThe risk or severity of hypotension can be increased when Thioproperazine is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Thioproperazine.Approved
BezitramideThioproperazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinThe risk or severity of hypotension can be increased when Thioproperazine is combined with Bioallethrin.Approved, Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
BitolterolThioproperazine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
BrexpiprazoleThioproperazine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineThioproperazine may decrease the vasoconstricting activities of Brimonidine.Approved
BromocriptineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Thioproperazine.Approved
BucindololBucindolol may increase the antihypertensive activities of Thioproperazine.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Thioproperazine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Thioproperazine.Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
BuprenorphineThioproperazine may increase the hypotensive activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Thioproperazine.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thioproperazine.Approved, Investigational
ButorphanolThioproperazine may increase the hypotensive activities of Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thioproperazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thioproperazine.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Thioproperazine is combined with Carboxyamidotriazole.Investigational
CarfentanilThioproperazine may increase the hypotensive activities of Carfentanil.Illicit, Investigational, Vet Approved
CaroverineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Thioproperazine.Approved
ChloroquineThe serum concentration of Thioproperazine can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thioproperazine.Approved
ChlorphentermineThioproperazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Thioproperazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineChlorpromazine may increase the antihypertensive activities of Thioproperazine.Approved, Investigational, Vet Approved
CilnidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Cinnarizine.Approved, Investigational
CirazolineThioproperazine may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Thioproperazine.Approved, Investigational
ClenbuterolThioproperazine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Clevidipine.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Clindamycin.Approved, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineThioproperazine may decrease the vasoconstricting activities of Clonidine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Thioproperazine.Experimental
ClozapineClozapine may increase the antihypertensive activities of Thioproperazine.Approved
CodeineThe risk or severity of hypotension and central nervous system depression can be increased when Thioproperazine is combined with Codeine.Approved, Illicit
CyclandelateThe risk or severity of hypotension can be increased when Thioproperazine is combined with Cyclandelate.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thioproperazine.Approved
Cycloguanil embonateThe serum concentration of Thioproperazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Cyclosporine.Approved, Investigational, Vet Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Thioproperazine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Thioproperazine.Investigational
DapsoneThe serum concentration of Thioproperazine can be increased when it is combined with Dapsone.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Darodipine.Experimental
DesipramineDesipramine may increase the orthostatic hypotensive activities of Thioproperazine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThioproperazine may decrease the vasoconstricting activities of Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thioproperazine.Approved
DexmedetomidineThioproperazine may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DexniguldipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Dexniguldipine.Experimental
DextroamphetamineThioproperazine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Thioproperazine.Approved
DextromoramideThioproperazine may increase the hypotensive activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneThioproperazine may increase the hypotensive activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe risk or severity of hypotension can be increased when Thioproperazine is combined with Dexverapamil.Experimental
DezocineThioproperazine may increase the hypotensive activities of Dezocine.Approved, Investigational
DiethylpropionThioproperazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DihydrocodeineThioproperazine may increase the hypotensive activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thioproperazine.Approved, Investigational
DihydroetorphineThioproperazine may increase the hypotensive activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineThioproperazine may increase the hypotensive activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of hypotension can be increased when Thioproperazine is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thioproperazine.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thioproperazine.Approved, Investigational
DiphenoxylateThioproperazine may increase the hypotensive activities of Diphenoxylate.Approved, Illicit
DipivefrinThioproperazine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Thioproperazine.Approved
DL-MethylephedrineThioproperazine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineThioproperazine may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineThioproperazine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DotarizineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.Approved
DoxepinDoxepin may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
DoxofyllineThioproperazine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe serum concentration of Thioproperazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thioproperazine.Approved, Vet Approved
DPDPEThioproperazine may increase the hypotensive activities of DPDPE.Experimental
DronedaroneDronedarone may increase the antihypertensive activities of Thioproperazine.Approved
DroperidolDroperidol may increase the antihypertensive activities of Thioproperazine.Approved, Vet Approved
DroxidopaThioproperazine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thioproperazine.Approved
EfonidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thioproperazine.Approved, Investigational
EmopamilThe risk or severity of hypotension can be increased when Thioproperazine is combined with Emopamil.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Thioproperazine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Thioproperazine is combined with Eperisone.Approved, Investigational
EphedraThioproperazine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineThioproperazine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineThioproperazine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineThioproperazine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioproperazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioproperazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thioproperazine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Thioproperazine.Experimental
EscitalopramEscitalopram may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
EtafedrineThioproperazine may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolThioproperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of hypotension can be increased when Thioproperazine is combined with Ethosuximide.Approved
EthylmorphineThioproperazine may increase the hypotensive activities of Ethylmorphine.Approved, Illicit
EtilefrineThioproperazine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidateThioproperazine may decrease the vasoconstricting activities of Etomidate.Approved
EtorphineThioproperazine may increase the hypotensive activities of Etorphine.Illicit, Vet Approved
FelodipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Fendiline.Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoterolThioproperazine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThioproperazine may increase the hypotensive activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Fish oilThe risk or severity of hypotension can be increased when Thioproperazine is combined with Fish oil.Approved, Nutraceutical
FlunarizineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Flunarizine.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Thioproperazine.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Thioproperazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Thioproperazine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Fluvoxamine.Approved, Investigational
FormoterolThioproperazine may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Thioproperazine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Thioproperazine.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Thioproperazine is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Thioproperazine is combined with Gallopamil.Investigational
GepefrineThioproperazine may decrease the stimulatory activities of Gepefrine.Experimental
GuanabenzThioproperazine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Thioproperazine.Approved, Investigational
HalofantrineThe serum concentration of Thioproperazine can be increased when it is combined with Halofantrine.Approved
HeroinThioproperazine may increase the hypotensive activities of Heroin.Approved, Illicit, Investigational
HexoprenalineThioproperazine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineThioproperazine may decrease the vasoconstricting activities of Higenamine.Investigational
HydrocodoneThioproperazine may increase the hypotensive activities of Hydrocodone.Approved, Illicit
HydromorphoneThioproperazine may increase the hypotensive activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyamphetamineThioproperazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Thioproperazine can be increased when it is combined with Hydroxychloroquine.Approved
IloperidoneThioproperazine may increase the antihypertensive activities of Iloperidone.Approved
ImipramineImipramine may increase the antihypertensive activities of Thioproperazine.Approved
IndacaterolThioproperazine may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Indalpine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Thioproperazine.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Thioproperazine.Withdrawn
Iofetamine I-123Thioproperazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thioproperazine.Approved
IsoetarineThioproperazine may decrease the vasoconstricting activities of Isoetarine.Approved
IsomethepteneThioproperazine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineThioproperazine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineThioproperazine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Isradipine.Approved, Investigational
KetobemidoneThioproperazine may increase the hypotensive activities of Ketobemidone.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Thioproperazine.Approved
LacidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Thioproperazine.Investigational
LercanidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Thioproperazine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved, Investigational
LevobunololThioproperazine may increase the hypotensive activities of Levobunolol.Approved
LevodopaThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThioproperazine may increase the hypotensive activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThioproperazine may increase the hypotensive activities of Levorphanol.Approved
LevosalbutamolThioproperazine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Lidoflazine.Experimental
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Thioproperazine.Approved, Investigational
LisdexamfetamineThioproperazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Thioproperazine.Experimental
LofentanilThioproperazine may increase the hypotensive activities of Lofentanil.Illicit
LofexidineThioproperazine may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LomerizineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Lomerizine.Experimental
LoperamideThe risk or severity of hypotension can be increased when Thioproperazine is combined with Loperamide.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Thioproperazine.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Thioproperazine.Approved
LumefantrineThe serum concentration of Thioproperazine can be increased when it is combined with Lumefantrine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Magnesium citrate.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe therapeutic efficacy of Thioproperazine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thioproperazine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Thioproperazine.Approved
MedetomidineThioproperazine may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MefloquineThe serum concentration of Thioproperazine can be increased when it is combined with Mefloquine.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Thioproperazine is combined with Menthol.Approved
MephedroneThioproperazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineThioproperazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Thioproperazine.Experimental
MeptazinolThioproperazine may increase the hypotensive activities of Meptazinol.Experimental
MequitazineThioproperazine may increase the arrhythmogenic activities of Mequitazine.Approved
MetaraminolThioproperazine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneThioproperazine may increase the hypotensive activities of Methadone.Approved
Methadyl AcetateThioproperazine may increase the hypotensive activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThioproperazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethotrimeprazineMethotrimeprazine may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
MethoxamineThioproperazine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineThioproperazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Thioproperazine is combined with Methsuximide.Approved
MethyldopaThioproperazine may decrease the vasoconstricting activities of Methyldopa.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Methylphenidate.Approved, Investigational
MetipranololThioproperazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thioproperazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Thioproperazine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Thioproperazine.Approved
MibefradilThe risk or severity of hypotension can be increased when Thioproperazine is combined with Mibefradil.Investigational, Withdrawn
MidodrineThioproperazine may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineThioproperazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Milnacipran.Approved, Investigational
MirabegronThioproperazine may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Thioproperazine.Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thioproperazine.Approved
MizoribineThe serum concentration of Thioproperazine can be increased when it is combined with Mizoribine.Investigational
MMDAThioproperazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thioproperazine.Approved, Investigational
MorphineThioproperazine may increase the hypotensive activities of Morphine.Approved, Investigational
MoxonidineThioproperazine may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Thioproperazine is combined with Naftopidil.Investigational
NalbuphineThioproperazine may increase the hypotensive activities of Nalbuphine.Approved
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Thioproperazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Thioproperazine.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Thioproperazine.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Neomycin.Approved, Vet Approved
NicardipineNicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
NicomorphineThioproperazine may increase the hypotensive activities of Nicomorphine.Experimental
NifedipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nifedipine.Approved
NiguldipineThioproperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nitrendipine.Approved, Investigational
NorepinephrineThioproperazine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineThioproperazine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NormethadoneThioproperazine may increase the hypotensive activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the antihypertensive activities of Thioproperazine.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Thioproperazine.Approved
OctopamineThioproperazine may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineOlanzapine may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
OlodaterolThioproperazine may decrease the vasoconstricting activities of Olodaterol.Approved
OpiumThioproperazine may increase the hypotensive activities of Opium.Approved, Illicit
OrciprenalineThioproperazine may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumThe risk or severity of hypotension can be increased when Thioproperazine is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
OxycodoneThe risk or severity of hypotension and central nervous system depression can be increased when Thioproperazine is combined with Oxycodone.Approved, Illicit, Investigational
OxyfedrineThioproperazine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Thioproperazine.Approved, Investigational
OxymorphoneThe risk or severity of hypotension and central nervous system depression can be increased when Thioproperazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may increase the antihypertensive activities of Thioproperazine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved, Investigational
PenfluridolThe risk or severity of hypotension can be increased when Thioproperazine is combined with Penfluridol.Experimental
PentazocineThioproperazine may increase the hypotensive activities of Pentazocine.Approved, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Thioproperazine.Approved, Investigational
PergolideThioproperazine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PethidineThioproperazine may increase the hypotensive activities of Pethidine.Approved
PhenazocineThioproperazine may increase the hypotensive activities of Phenazocine.Experimental
PhendimetrazineThioproperazine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thioproperazine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thioproperazine.Approved, Investigational
PhenoperidineThioproperazine may increase the hypotensive activities of Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Thioproperazine.Approved
PhentermineThioproperazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolaminePhentolamine may increase the antihypertensive activities of Thioproperazine.Approved
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Thioproperazine.Approved
PhenylpropanolamineThioproperazine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinaveriumThe risk or severity of hypotension can be increased when Thioproperazine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved, Investigational
PiperaquineThe serum concentration of Thioproperazine can be increased when it is combined with Piperaquine.Approved, Investigational
PirbuterolThioproperazine may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThioproperazine may increase the hypotensive activities of Piritramide.Approved, Investigational
PizotifenThioproperazine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Thioproperazine.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
PramipexoleThioproperazine may increase the sedative activities of Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the antihypertensive activities of Thioproperazine.Approved
PregabalinThe therapeutic efficacy of Thioproperazine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolThioproperazine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Prenylamine.Withdrawn
PrimaquineThe serum concentration of Thioproperazine can be increased when it is combined with Primaquine.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thioproperazine.Approved, Investigational
ProcaterolThioproperazine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProguanilThe serum concentration of Thioproperazine can be increased when it is combined with Proguanil.Approved
PromazinePromazine may increase the antihypertensive activities of Thioproperazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Thioproperazine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Thioproperazine.Approved
PropericiazineThioproperazine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Thioproperazine.Approved
PropiverineThioproperazine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropranololThe serum concentration of Propranolol can be increased when it is combined with Thioproperazine.Approved, Investigational
ProtokylolThioproperazine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thioproperazine.Approved
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Thioproperazine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with Thioproperazine.Approved, Vet Approved
PyrimethamineThe serum concentration of Thioproperazine can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe serum concentration of Thioproperazine can be increased when it is combined with Pyronaridine.Investigational
QuetiapineQuetiapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.Approved
QuinacrineThe serum concentration of Thioproperazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Thioproperazine.Approved, Investigational
QuinidineThioproperazine may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineThe serum concentration of Thioproperazine can be increased when it is combined with Quinine.Approved
RacepinephrineThioproperazine may increase the antihypertensive activities of Racepinephrine.Approved
RactopamineThioproperazine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RadicicolThe serum concentration of Thioproperazine can be increased when it is combined with Radicicol.Experimental
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioproperazine.Approved
RemifentanilThioproperazine may increase the hypotensive activities of Remifentanil.Approved
ReproterolThioproperazine may decrease the vasoconstricting activities of Reproterol.Investigational
RilmenidineThioproperazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolThioproperazine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
RitobegronThioproperazine may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineThioproperazine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Thioproperazine.Approved
RomifidineThioproperazine may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThioproperazine may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Rotigotine.Approved
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Thioproperazine.Approved, Vet Approved
SalmeterolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Thioproperazine.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Thioproperazine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Thioproperazine is combined with Seletracetam.Investigational
SertralineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Sertraline.Approved
SildenafilSildenafil may increase the hypotensive activities of Thioproperazine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Thioproperazine.Approved
SinefunginThe serum concentration of Thioproperazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SolabegronThioproperazine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
SufentanilThioproperazine may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Thioproperazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Thioproperazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideThioproperazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Thioproperazine.Approved, Investigational
SynephrineThioproperazine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Thioproperazine.Approved, Investigational
TafenoquineThe serum concentration of Thioproperazine can be increased when it is combined with Tafenoquine.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Thioproperazine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
TapentadolThioproperazine may increase the hypotensive activities of Tapentadol.Approved
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thioproperazine.Approved
TerazosinTerazosin may increase the antihypertensive activities of Thioproperazine.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Thioproperazine.Approved
TerodilineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Thioproperazine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thioproperazine.Approved, Investigational
TetrahydropalmatineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Tetrahydropalmatine.Investigational
TetrandrineThe risk or severity of QTc prolongation can be increased when Tetrandrine is combined with Thioproperazine.Experimental
TetryzolineThioproperazine may decrease the vasoconstricting activities of Tetryzoline.Approved
TheophyllineTheophylline may increase the hypotensive activities of Thioproperazine.Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the antihypertensive activities of Thioproperazine.Approved, Withdrawn
TilidineThioproperazine may increase the hypotensive activities of Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
TizanidineThioproperazine may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Thioproperazine.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Thioproperazine is combined with Tolfenamic Acid.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Thioproperazine.Approved
TramadolThe risk or severity of hypotension and central nervous system depression can be increased when Thioproperazine is combined with Tramadol.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Thioproperazine is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thioproperazine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
TretoquinolThioproperazine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Thioproperazine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Thioproperazine is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Thioproperazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the antihypertensive activities of Thioproperazine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TulobuterolThioproperazine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Thioproperazine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Thioproperazine.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Thioproperazine.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Thioproperazine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Thioproperazine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Venlafaxine.Approved
VerapamilThioproperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
VilanterolThioproperazine may decrease the vasoconstricting activities of Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Thioproperazine.Approved
VinpocetineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Vinpocetine.Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Thioproperazine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Thioproperazine is combined with WIN 55212-2.Experimental
XamoterolThioproperazine may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineThioproperazine may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineThioproperazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Thioproperazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Thioproperazine.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thioproperazine.Approved, Investigational
ZolpidemThioproperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of hypotension can be increased when Thioproperazine is combined with Zonisamide.Approved, Investigational
ZuclopenthixolZuclopenthixol may increase the antihypertensive activities of Thioproperazine.Approved, Investigational
Food Interactions
  • Avoid alcohol
  • Take with food to avoid irritation

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015559
KEGG Drug
D08585
PubChem Compound
9429
PubChem Substance
46507111
ChemSpider
9058
BindingDB
81793
ChEBI
59120
ChEMBL
CHEMBL609109
PharmGKB
PA164754875
Wikipedia
Thioproperazine
ATC Codes
N05AB08 — Thioproperazine
AHFS Codes
  • 28:16.08.24 — Phenothiazines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral10 mg
Prices
Unit descriptionCostUnit
Majeptil 10 mg Tablet0.6USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)140 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0569 mg/mLALOGPS
logP3.09ALOGPS
logP2.83ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)8.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area47.1 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity126.95 m3·mol-1ChemAxon
Polarizability49.62 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier+0.9629
Caco-2 permeable-0.6568
P-glycoprotein substrateSubstrate0.7908
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.7979
Renal organic cation transporterNon-inhibitor0.5396
CYP450 2C9 substrateNon-substrate0.7704
CYP450 2D6 substrateNon-substrate0.8194
CYP450 3A4 substrateSubstrate0.5366
CYP450 1A2 substrateNon-inhibitor0.8243
CYP450 2C9 inhibitorNon-inhibitor0.8758
CYP450 2D6 inhibitorInhibitor0.6293
CYP450 2C19 inhibitorNon-inhibitor0.7713
CYP450 3A4 inhibitorInhibitor0.6338
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6663
Ames testNon AMES toxic0.7056
CarcinogenicityNon-carcinogens0.8109
BiodegradationNot ready biodegradable0.9934
Rat acute toxicity2.6623 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7265
hERG inhibition (predictor II)Non-inhibitor0.5303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-01vo-9411000000-e918c0715fd27f21a62f
GC-MS Spectrum - EI-BGC-MSsplash10-0229-6924100000-fcb76747a5faaee6b722
GC-MS Spectrum - CI-BGC-MSsplash10-0002-1001900000-0b26a1120865f1ac9f3a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / N-methylpiperazines / Organosulfonamides / Benzenoids / 1,4-thiazines / Aminosulfonyl compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 2 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / N-methylpiperazine / N-alkylpiperazine / Para-thiazine / 1,4-diazinane / Piperazine
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, sulfonamide, N-alkylpiperazine, N-methylpiperazine (CHEBI:59120)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  3. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263]
  4. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. [PubMed:11755134]
  2. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. [PubMed:9760039]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]

Drug created on August 29, 2007 14:17 / Updated on August 13, 2018 10:11